EUCTR2004-001779-20-IT
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone For The Treatment of Antiretroviral-Experienced Non CCR5-Tropic HIV-1 Infected Subject
Pfizer LTD, Pfizer Global RD-Sandwich Laboratories-I.P.C. 5820 个研究点目标入组 192 人2007年9月17日
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- Pfizer LTD, Pfizer Global RD-Sandwich Laboratories-I.P.C. 582
- 入组人数
- 192
- 状态
- 进行中（未招募）
- 最后更新
- 14年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
排除标准
- 未提供
结局指标
主要结局
未指定
相似试验
进行中（未招募）
1 期
A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) recipients with bronchiolitis obliterans syndrome (BOS) grade 1-2Bronchiolitis Obliterating Syndrome (SBO) grade 1 or 2 in patients with pulmonary transplantation.MedDRA version: 20.0 Level: PT Classification code 10029888 Term: Obliterative bronchiolitis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]EUCTR2018-001747-31-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)80
已完成
3 期
A phase III study of ONO-4538(ONO-4538-52/TASUKI-52)JPRN-jRCT2080223505ONO PHARMACEUTICAL CO.,LTD.530
招募中
不适用
Double-blind Randomized Multi-center Trial Regarding the Effects of Solution for Gemcitabine on Frequency and Degree of Vascular Pain in Patients with CancerJPRN-UMIN000001827Tohoku University Translational Research Center90
未知
3 期
A Double-Blind, Randomized, Multicentre Trial Comparing the Efficacy and Tolerability of 250mg of Faslodex (Long Acting ICI 182,780) With 20mg of Nolvadex (Tamoxifen) in Postmenopausal Women With Advanced Breast CancerBreast Cancer MetastasisJPRN-jRCT2080220407AstraZeneca
已完成
2 期
The survival and quality of life benefits of melatonin when administered to cancer patients at the optimal time of dayThe affects of adjuvant melatonin on the outcomes of stage III and IV non small cell lung cancer patientsCancerISRCTN16419921Cancer Treatment Centers of America®90